Research has found that not only does stopping treatment typically result in weight regain, but it can also worsen cardiometabolic risk factors like obesity, high blood pressure , high cholesterol, and insulin resistance
Tirzepatide at 10 mg produces roughly 1,560 kcal per day of intervention with a similar plateau timeline
On August 27, 2025, the FDA approved the first generic version of liraglutide (Saxenda) for weight loss in adults and adolescents with obesity and adults with overweight and at least one weight-related comorbid condition
Seek immediate medical care for severe persistent abdominal pain, repeated vomiting, inability to keep fluids down, reduced urine output, visual changes, chest pain, or difficulty breathing
Dose AI tracks your injection schedule, rotates injection sites for you, and reminds you when the next shot is due
For some, coaching and kitchen habits are enough